Potential targeted therapies for ovarian cancer beyond PARP inhibitors

This review aimed to investigate the clinical utility of next-generation sequencing (NGS) in treating high-grade serous ovarian cancer (HGSC) with targeted therapies other than Poly (ADP-ribose) polymerase (PARP) inhibitors. The search was performed in PubMed and Embase. The literature search combined screening the reference sections of relevant studies. A total of 1882 studies were screened, and 6 case reports met the inclusion criteria. The patients were treated with trametinib, crizotinib, alectinib, a protein kinase B (AKT) inhibitor, everolimus-letrozole or trastuzumab-pertuzumab. A partial response was observed in patients (n = 3) treated with trametinib, crizotinib or trastuzumab-pertuzumab. One patient treated with alectinib had a complete response, while the patients (n = 2) treated with AKT inhibitor or everolimus-letrozole had stable disease and progressive disease. The results suggest that NGS may have a role in identifying effective targeted therapies for patients diagnosed with HGSC. Further research, including basket trials, is needed to confirm the results.